Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive Symptoms
Effects of Individualized Resting-State fMRI-Guided Intermittent Theta-Burst Stimulation on Depressive and Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome: A Randomized, Double-Blind, Sham-Controlled Trial
This randomized, double-blind, sham-controlled trial aims to evaluate the effects of individualized intermittent theta-burst stimulation (iTBS) on depressive and gastrointestinal symptoms in patients with irritable bowel syndrome (IBS) and depressive symptoms.
A total of 60 eligible participants will be randomly assigned in a 1:1 ratio to active or sham stimulation. Individualized stimulation targets within the left dorsolateral prefrontal cortex (DLPFC) will be identified using resting-state functional magnetic resonance imaging (fMRI).
Participants will receive 10 stimulation sessions over two weeks. Clinical assessments and multimodal brain MRI will be performed at baseline and at the end of Week 2. The primary outcome will be the change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).
An optional ancillary study involving paired stool sample collection at baseline and Week 2 is planned to support future exploratory investigations of gut microbiota and its associations with clinical symptoms and brain network characteristics. This ancillary component will be implemented only after the relevant ethics approval and additional informed consent have been obtained.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Jie Li
- Numéro de téléphone: +8615988858667
- E-mail: jie_sweethz@163.com
Lieux d'étude
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310015
- Recrutement
- The Affiliated Hospital of Hangzhou Normal University
-
Contact:
- Jie Li
- Numéro de téléphone: +8615988858667
- E-mail: jie_sweethz@163.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Right-handed individuals.
- Diagnosis of irritable bowel syndrome according to the Rome IV criteria.
- Presence of depressive symptoms, defined as a HAMD-17 score greater than 7.
- Inadequate response to at least two months of conventional treatment for IBS.
- Ability to understand the study procedures and provide written informed consent.
- Willingness and ability to undergo MRI examinations and complete the study assessments.
Exclusion Criteria:
- Contraindications to MRI or transcranial magnetic stimulation.
- Known food intolerance, relevant gastrointestinal surgery, or gastrointestinal diseases other than IBS that may explain the symptoms.
- History of significant neurological disorders or psychiatric disorders other than the depressive symptoms under investigation.
- History of intracranial surgery.
- Intracranial mass lesions or severe white matter abnormalities detected by MRI.
- Other conditions that, in the investigator's judgment, would make participation inappropriate or unsafe.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Active Individualized iTBS
Participants will receive individualized intermittent theta-burst stimulation targeting the left dorsolateral prefrontal cortex. The stimulation target will be identified using resting-state fMRI-guided functional connectivity analysis. Stimulation will be delivered at 90% of the resting motor threshold, with 1,800 pulses per session. Each session will comprise three blocks of 600 pulses, separated by approximately 15-minute intervals. Participants will receive five sessions per week for two weeks, for a total of 10 sessions. |
Resting-state fMRI-guided iTBS targeting the individualized left dorsolateral prefrontal cortex at 90% of resting motor threshold, delivering 1,800 pulses per session for 10 sessions over two weeks. |
|
Comparateur factice: Sham iTBS
Participants will undergo a sham stimulation procedure with a schedule comparable to the active intervention. The stimulation coil will be positioned at 90 degrees to minimize effective cortical stimulation. Participants will receive five sessions per week for two weeks, for a total of 10 sessions. |
A sham stimulation procedure using a coil positioned at 90 degrees, with a treatment schedule comparable to active iTBS. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in Depressive Symptom Severity Assessed by HAMD-17 at Week 2
Délai: Baseline and end of Week 2
|
Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). A higher score indicates greater depressive symptom severity. The change from baseline to the end of Week 2 will be compared between the active and sham stimulation groups. |
Baseline and end of Week 2
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in IBS Symptom Severity at Week 2
Délai: Baseline and end of Week 2
|
IBS symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). Changes from baseline to the end of Week 2 will be compared between groups. |
Baseline and end of Week 2
|
|
Change From Baseline in Abdominal Pain Intensity at Week 2
Délai: Baseline and end of Week 2
|
Abdominal pain intensity will be evaluated using a Visual Analog Scale (VAS). |
Baseline and end of Week 2
|
|
Change From Baseline in Pain Severity Assessed by the Short-Form McGill Pain Questionnaire at Week 2
Délai: Baseline and end of Week 2
|
Pain-related symptoms will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ). |
Baseline and end of Week 2
|
|
Change From Baseline in Anxiety Symptom Severity at Week 2
Délai: Baseline and end of Week 2
|
Anxiety symptom severity will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14). |
Baseline and end of Week 2
|
|
Change From Baseline in IBS-Related Quality of Life at Week 2
Délai: Baseline and end of Week 2
|
IBS-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL). |
Baseline and end of Week 2
|
|
MRI Outcomes
Délai: Baseline and end of Week 2
|
functional and structural brain network analyses |
Baseline and end of Week 2
|
|
Safety Outcomes
Délai: Baseline and end of Week 2
|
adverse-event incidence |
Baseline and end of Week 2
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- IBS_dep-iTBS-2025
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .